Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 333

1.

Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.

Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L.

Vaccine. 2006 Jan 16;24(3):254-62. Epub 2005 Aug 15.

PMID:
16129526
2.

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.

Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M.

Hum Vaccin. 2005 Jan-Feb;1(1):37-42. Epub 2005 Jan 12.

PMID:
17038827
3.

Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

Durrer P, Glück U, Spyr C, Lang AB, Zurbriggen R, Herzog C, Glück R.

Vaccine. 2003 Oct 1;21(27-30):4328-34.

PMID:
14505915
4.

Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.

Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L.

Expert Rev Vaccines. 2011 Mar;10(3):365-75. doi: 10.1586/erv.10.172. Review.

PMID:
21434804
5.

Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine.

Muszkat M, Greenbaum E, Ben-Yehuda A, Oster M, Yeu'l E, Heimann S, Levy R, Friedman G, Zakay-Rones Z.

Vaccine. 2003 Mar 7;21(11-12):1180-6.

PMID:
12559796
6.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

7.
8.

Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.

Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L.

Vaccine. 2006 Mar 6;24(10):1601-8. Epub 2005 Oct 14.

PMID:
16303215
9.

A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.

Samdal HH, Bakke H, Oftung F, Holst J, Haugen IL, Korsvold GE, Kristoffersen AC, Krogh G, Nord K, Rappuoli R, Berstad AK, Haneberg B.

Hum Vaccin. 2005 Mar-Apr;1(2):85-90. Epub 2005 Mar 16.

PMID:
17038826
10.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.

Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099. Epub 2011 Aug 2.

PMID:
21816199
11.

Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies.

Powers DC, Murphy BR, Fries LF, Adler WH, Clements ML.

J Am Geriatr Soc. 1992 Feb;40(2):163-7.

PMID:
1740601
12.

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

Jones T, Allard F, Cyr SL, Tran SP, Plante M, Gauthier J, Bellerose N, Lowell GH, Burt DS.

Vaccine. 2003 Sep 8;21(25-26):3706-12.

PMID:
12922101
13.

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge.

Plante M, Jones T, Allard F, Torossian K, Gauthier J, St-Félix N, White GL, Lowell GH, Burt DS.

Vaccine. 2001 Oct 12;20(1-2):218-25.

PMID:
11567767
14.

Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.

Coulter A, Harris R, Davis R, Drane D, Cox J, Ryan D, Sutton P, Rockman S, Pearse M.

Vaccine. 2003 Feb 14;21(9-10):946-9.

PMID:
12547607
15.

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.

Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.

Vaccine. 2006 May 1;24(18):3990-4006. Epub 2005 Dec 27.

PMID:
16516356
16.

Local immune responses following nasal delivery of an adjuvanted influenza vaccine.

Scheerlinck JP, Gekas S, Yen HH, Edwards S, Pearse M, Coulter A, Sutton P.

Vaccine. 2006 May 1;24(18):3929-36. Epub 2006 Feb 28.

PMID:
16540213
17.

Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.

Bakke H, Samdal HH, Holst J, Oftung F, Haugen IL, Kristoffersen AC, Haugan A, Janakova L, Korsvold GE, Krogh G, Andersen EA, Djupesland P, Holand T, Rappuoli R, Haneberg B.

Scand J Immunol. 2006 Mar;63(3):223-31.

18.

Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.

Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, Morag A, Zakay-Rones Z.

J Med Virol. 2001 Sep;65(1):178-84.

PMID:
11505461
19.

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.

Vaccine. 2010 Feb 17;28(7):1740-5. doi: 10.1016/j.vaccine.2009.12.014. Epub 2009 Dec 22.

PMID:
20034605
20.

Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais.

Phonrat B, Pitisuttithum P, Chamnanchanunt S, Puthavathana P, Ngaosuwankul N, Louisirirotchanakul S, Dhitavat J, Thirapakpoomanunt S, Chokevivat V, Wibulpolprasert S.

Vaccine. 2013 Mar 1;31(11):1503-9. doi: 10.1016/j.vaccine.2012.12.082. Epub 2013 Jan 11.

PMID:
23318149

Supplemental Content

Support Center